Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1
Abstract
This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 , online only). Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline .
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (11)
Joshua E. Reuss
Georgetown University, Washington, DC
Nofisat Ismaila
American Society of Clinical Oncology (ASCO), Alexandria, VA, US
Amith Ahluwalia
Confluence Health Wenatchee Valley Hospital and Clinics, Wenatchee, WA
Toby Campbell
University of Wisconsin, Madison, WI
Jill Feldman
Patient Advocate EGFR Resisters Deerfield Illinois USA
Shirish Gadgeel
Henry Ford Cancer Institute/Henry Ford Health System, Detroit, MI
Michael Mullane
Aurora Cancer Care, Mount Pleasant, WI
Carolyn J. Presley
Eric K. Singhi
University of Texas MD Anderson Cancer Center, Houston, TX
Jennifer Marie Suga
Kaiser Permanente Vallejo Medical Center, Vallejo, CA
Sonam Puri